Multiple Myeloma
Conference Coverage
Myeloma patients over age 70 can benefit from auto-HC transplant
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
Conference Coverage
High complete response rate seen with novel CAR-T for myeloma
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
News
Early lenalidomide may delay progression of smoldering myeloma
Researchers said the findings from the phase 3 study support early treatment as the new standard of care in patients with high-risk smoldering...
News
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
Levofloxacin looks like a promising addition to therapy, but the researchers cautioned that antibiotic resistance must be considered.
Article
Multiple Myeloma Federal Health Care Data Trends
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
News
Recombinant vaccine cut herpes zoster rate in immunocompromised patients
In a randomized clinical trial of 1,846 adults who had undergone autologous HSCT, herpes zoster cases were seen in 49 and 136 individuals in the...
News
FDA approves Xpovio for relapsed/refractory multiple myeloma
The oral therapy was approved for patients who have received at least four prior therapies and whose disease is resistant to several other forms...